Peptide
KPV
Three-amino-acid fragment from the end of α-MSH with an anti-inflammatory effect in cells and mice. There are no published studies in humans.
Regulatory status
Not approved
Family
α-MSH-derived tripeptide (melanocortin)
Where it acts
Digestive and weight · Immunity and defense
Also known as
Lys-Pro-Val, lysine-proline-valine, α-MSH (11-13)
Regulatory status
FDA (US): Not approved. The FDA notes that there are no human exposure data.
EMA (EU): No application
Dose
There is no established dose in humans.
Safety
No safety data in humans. Products sold as a "research peptide" have no quality control. Its use only makes sense in research or under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
reduces Low preclinical (A) animals / laboratory
In two mouse models of colitis (DSS and TNBS), oral KPV reduced inflammation and proinflammatory cytokines. In vitro it acted at nanomolar concentrations.
View the study (preclinical) →In depth
Where it acts
Digestion and weight, Immunity and defense
How it works
Enters cells of the intestine and immune system through the peptide transporter PepT1. Inside, it slows the inflammatory NF-κB and MAP kinase pathways and reduces the release of proinflammatory cytokines.
What the evidence says
In people
There are no published trials in people.
In animals or the laboratory
- Colitis in mice. In two mouse models of colitis (DSS and TNBS), oral KPV reduced inflammation and proinflammatory cytokines. In vitro it acted at nanomolar concentrations. PubMed 18061177
References
- PubMed 18061177
Information, not medical advice. Prescription or unapproved peptides should only be used under medical supervision.